Latigo Biotherapeutics reported Phase 2 evidence for LTG-001, an oral therapy being evaluated as a non-opioid option after surgery. In the trial of 343 patients undergoing tummy tuck (abdominoplasty), participants were randomized to high-dose LTG-001, low-dose LTG-001, placebo, or acetaminophen plus hydrocodone. Both LTG-001 dose arms showed statistically significant pain relief compared with placebo at 48 hours. The high-dose group also used less supplemental oxycodone than placebo, with safety data indicating higher overall adverse-event rates in placebo and some dose-arm differences including fever and lightheadedness. The results place Latigo in a fast-moving segment of post-operative pain programs seeking alternatives to opioids, with trial design targeting clinically meaningful rescue-usage behavior, not only symptom scales.